A Prospective Non-interventional Study Investigating the Treatment Effect of NovoMix 30 (Biphasic Insulin Aspart 30) in a Real World Adult Population With Type 2 Diabetes in Algeria
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms B Simple
- Sponsors Novo Nordisk
Most Recent Events
- 05 Jun 2020 According to clinicaltrials.gov the study was withdrawn as per the sponsor's decision.
- 02 Jun 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Apr 2020 Planned End Date changed from 6 May 2021 to 28 Jun 2021.